All News

4 April 2012

UCB and Amgen Initiate Sclerostin Antibody Phase 3 program in patients with postmenopausal osteoporosisAntibodies

3 April 2012

Immunomedics Develops Bispecific Hexavalent Antibodies for Diverse Epithelial CancersAntibodies

2 April 2012

Lilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR MeetingAntibodies

2 April 2012

Immunomedics Reports Clinical Results of Pretargeted Radioimmunotherapy of Colorectal CancerAntibodies

31 March 2012

ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product CandidateAntibodies

30 March 2012

Genentech’s Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast CancerAntibodies

30 March 2012

New Drug Application Approval for POTELIGEO (Mogamulizumab) Injection in Japan, a Therapeutic Antibody for Adult T-cell Leukemia-Lymphoma (ATL)Antibodies

29 March 2012

Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of MedicineAntibodies

29 March 2012

Lilly’s Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint in Phase II Study in Patients With Chronic Plaque PsoriasisAntibodies

27 March 2012

Morphotek, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerAntibodies

27 March 2012

Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of Clinical OncologyAntibodies

26 March 2012

First Patient Enrolled in CSL Behring PATH Trial to Evaluate Immune Globulin Subcutaneous (Human) 20% Liquid, Hizentra, in the Treatment of CIDPAntibodies

26 March 2012

Sanofi and Regeneron Report Phase 2 Data for Potential First-in-Class Lipid-Lowering PCSK9 AntibodyAntibodies

26 March 2012

Celtic Therapeutics Launches $50M Antibody Drug Conjugates Development Company with 10 ADC Development ProgramsAntibodies

26 March 2012

Amgen’s PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b StudyAntibodies

24 March 2012

BT-062 demonstrates rapid and complete tumor eradication in preclinical studiesAntibodies

24 March 2012

Roche’s Herceptin given by subcutaneous injection offers greater convenience to patients and reduces overall healthcare costs compared to standard IV infusionAntibodies

24 March 2012

Synthon Pharmaceuticals Successfully Concluded Phase I Clinical Trial for TrastuzumabAntibodies

24 March 2012

Daiichi Sankyo Files for Approval in Japan to Market AMG 162 (denosumab), a Treatment for OsteoporosisAntibodies

21 March 2012

Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 AntibodyAntibodies

19 March 2012

Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCLAntibodies

15 March 2012

Abbott Announces Patient Enrollment in Two Phase 3 Studies of HUMIRA® (adalimumab) for Moderate to Severe Hidradenitis SuppurativaAntibodies

13 March 2012

biOasis’ BT2111-Herceptin(R) Program Achieves Significant Positive Results From Antibody Dependent Cell-Mediated Cytotoxicity AssayAntibodies

9 March 2012

Peregrine Reports Data From Phase II Front-Line Lung Cancer TrialAntibodies

9 March 2012

Study Establishes XOMA’s XMetA as the First Allosteric Insulin Receptor-Activating Antibody to Improve Glycemic Control In VivoAntibodies

6 March 2012

MorphoSys Completes Enrollment in MOR103 Phase 1b/2a Rheumatoid Arthritis TrialAntibodies

5 March 2012

Anthera Pharmaceuticals Completes Interim Analysis of PEARL-SC Clinical Trial with BlisibimodAntibodies

3 March 2012

Recruitment of patients completed in phase II study with BI-204Antibodies

2 March 2012

Genentech’s ACTEMRA Monotherapy Showed Superior Improvement in Rheumatoid Arthritis Signs and Symptoms Versus Adalimumab MonotherapyAntibodies

27 February 2012

FDA approves protocol amendment needed to conduct the final analysis of the pivotal RENCAREX Phase III trialAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals